



Research Article

Copy Right@ Kang-Wei Chang

# Evaluating The Effects of Traditional Herbal Medicine X-911 on Cytokine Expression and Glucose Uptake in LL2 Cells With <sup>18</sup>F-FDG/MicroPET

Shiou-Shiow Farn<sup>1</sup>, Yu-An Chen<sup>2</sup> and Kang-Wei Chang<sup>3,4\*</sup>

<sup>1</sup>Division of Isotope Application, Institute of Nuclear Energy Research, Taiwan

<sup>2</sup>Department of Health and Leisure Management, Yuanpei University of Medical Technology, Taiwan

<sup>3</sup>Taipei Neuroscience Institute, Taipei Medical University, Taiwan

<sup>4</sup>Laboratory Animal Center, Taipei Medical University, Taiwan

\*Corresponding author: K.W Chang, Ph.D., Taipei Medical University, Taipei Neuroscience Institute, No. 250 Wu-Hsing Street, Taipei city, Taiwan.

**To Cite This Article:** Shiou-Shiow Farn, Yu-An Chen, Kang-Wei Chang. Evaluating The Effects of Traditional Herbal Medicine X-911 on Cytokine Expression and Glucose Uptake in LL2 Cells With <sup>18</sup>F-FDG/MicroPET. *Am J Biomed Sci & Res.* 2021 - 14(1). *AJBSR.MS.ID.001954*.

DOI: [10.34297/AJBSR.2021.14.001954](https://doi.org/10.34297/AJBSR.2021.14.001954).

Received: 📅 July 21, 2021; Published: 📅 August 31, 2021

## Abstract

Traditional Chinese medicine (TCM) is empirically based, used to activate circulation alone or in combination with anticancer drugs. X-911, a kind of TCM extracted from plant sterols, optimal functioning of the immune system. To study the independent or combined use of X-911 in the treatment of allograft animal model on assessment of the effects of this treatment on tumor growth and cytokine expression was performed. After LL2 implantation, we administered X-911 (0.25 g or 0.125 g) for two weeks. Tumor growth, microPET imaging (<sup>18</sup>F-FDG) and cytokine assay were measured. Tumor glycolysis was obtained from <sup>18</sup>F-FDG microPET imaging, and cytokine assay between T cell helper 1 (Th1) and Th2 cells will perform analysis by multiplex cytokine assay. Accumulated inhibition of tumor growth by X-911 and changed the balance between T cell helper 1 (Th1) and Th2 cells by increasing Th1 cytokine expression, thus inhibiting tumor growth. Identified the functional image and biological mechanism of action of a TCM and demonstrate its curative effects on the body.

**Keywords:** <sup>18</sup>F-FDG/microPET, Traditional Chinese medicine, Cytokine

## Introduction

Traditional Chinese medicine (TCM) is empirically based, with a history of over 4000 years, and is used widely in China, Japan, Korea, Singapore, and elsewhere [1]. In TCM, the biological ingredients of herbal remedies are extracted from natural substances: plants, animal parts, shells, insects, and even stones and minerals. TCM is commonly used to nourish the blood, activate circulation, alleviate pain, regulate menstruation and attack tumor tissues, alone or in combination with anticancer drugs [2]. TCM can be used in cancer prophylaxis and/or treatment, for example, as *Phyllanthus urinaria* protects the liver from hepatocarcinogenesis and has shown anticancer activity [3]. *Sho-saiko-to* has hepatoprotective effects

in various liver injury experiments, including the injury induced with CCl<sub>4</sub> and D-galactosamine [4,5]. *Paeoniae radix* (PR) improves blood flow by its endothelium-dependent vasodilator action and potential antiaging and anticarcinogenesis activities [6].

X-911, extracted from plant sterols, essential nutrients been taken daily for the optimal functioning of the immune system, were first described in 1922 [7]. Sterols can enhance the cellular response of T lymphocytes, both in vitro and in vivo, and have biological importance in the control of plasma cholesterol levels [8]. Their potential as cancer-fighting molecules and their anti-inflammatory properties could also be useful in the managing of



chronic conditions [9]. In this study, we measured the dimensions of the tumor with physical tools and using  $^{18}\text{F}$ -FDG PET, to determine the functional outcomes of the tumors. There were significant differences in the levels of TNF- $\alpha$  and granulocyte-macrophage colony-stimulating factor (GM-CSF), which are related to T-helper 1 (TH1) cells, which improve the balance between TH1/TH2 in tumor cells. We demonstrate that X-911 induces a type I immunological reaction that increases TH1 cell activity and reduces the tumor volume.

## Materials and methods

### Animal model and cell line

#### Animal

Test species: Nude mice. Source: BioLASCO Taiwan Co., Ltd., Taipei, Taiwan. All animal was approved by the Ethical Animal Use Committee of the Institute of Nuclear Energy Research (INER) Atomic Energy Council.

#### Cell Line and Inoculation

Lewis mouse lung carcinoma (LL2) cells were cultured in high-glucose Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin solution. LL2 cells ( $2 \times 10^6$ ) were injected subcutaneously at a single location within the right leg over 15 s, using a 30-gauge needle.

### Physical Measurement of Tumor Size

After implantation for one week, the tumor volume ( $\text{mm}^3$ ) was determined daily. The tumor size along three orthogonal diameters was measured with calipers and the corresponding tumor volume was calculated as  $d_1 \times d_2 \times d_3$  ( $d_1$  as longest diameter,  $d_2$  as diameter perpendicular, and  $d_3$  as the height of the tumor).

### X-911 Feeding

X-911 was supplied by the ASC International Company. Extract from the plant is used as a TCM for human health. X-911 (0.25 g or 0.125 g) in sterile water was fed to the nude mice twice daily for two weeks. All nude mice were allocated to one of five groups, as shown in Table 1.

**Table 1:** Overview of the group 1 to 5 (n = 3) feeding with X-911.

Test No.	X-911 Treatment
Group 1	0.25 g twice a day, treated at 8 days after LL2 implanted
Group 2	0.125 g twice a day, treated at 8 days after LL2 implanted
Group 3	N/A
Group 4	0.5 g twice a day, treated at 14 days before LL2 implanted and until the end of study
Group 5	0.5 g twice a day, pretreated at 14 days before LL2 implanted

### MicroPET Procedure

The animals were anesthetized using 1 L/min 2% isoflurane (100% oxygen). After anesthetized, mice were given 15 MBq  $^{18}\text{F}$ -FDG via the lateral tail vein. Distribution for thirty minutes, static imaging (10 min) single-frame scans were acquired with a small-animal PET camera (microPET R4; Concorde Microsystems Inc.). The region of interest (ROI) was manually placed over the tumor region. ROI analysis of the reconstructed images was performed with ASIPro software (Concorde Microsystems Inc.) to determine the tumor volume by microPET and  $^{18}\text{F}$ -FDG uptake (%ID/g).


### Cytokine Assays

The supernatants of the blood serum were collected from the mice at the end of the study for assays. Concentrations of the cytokines IL1 $\beta$ , IL2, IL4, IL5, IL10, GM-CSF, IFN- $\gamma$ , and TNF- $\alpha$  were determined using the mouse Bio-Plex Multiplex Cytokine Th1/Th2 Assay kit and Cytokine Reagent kit (Bio-Rad Laboratories, Hercules, CA, USA). Data from the reactions were then acquired and analyzed with the Bio-Plex suspension array system (Luminex 100 system) from Bio-Rad Laboratories.

## Results

### Physical Measurement of Tumor Size

The LL2 Lewis murine lung carcinoma had been implanted in the right leg of each nude mouse; the tumor volume was about  $100 \text{ mm}^3$  and was considered ready for use in the study. As shown in Figure 1, eighteen days after implantation, the tumor volumes were significantly different in different groups.




**Figure 1:** The growth curve of tumor volume changed, measured by physical determination after implantation with LL2 cells. Recorded on all animals before starting implantation at day 8 (D8) to the end of the study period (D29). Data are means  $\pm$  SD (n = 3).


### MicroPET Procedure

In the microPET imaging study, the difference between the groups on day 21 and day 28 was showed in Figure 2 and data

analysis in Figure 3 & 3A was used microPET to determine the <sup>18</sup>F-FDG in the tumors of group 3 was found but was similar in the tumor volume on day 21 and day 28. However, highest uptake of other groups (Figure 3B).



**Figure 2:** MicroPET images showing the distribution of radioactivity in LL2 implanted nude mice after i.v. administration of 15 MBq of <sup>18</sup>F-FDG at different period of day 21 and day 28. A to E were the microPET images of day 21, and F to J were the day 28. A and F were the condition of group 1, B and G were group 2, C and H were group 3, D and I were group 4, and E and J were group 5. The region of interest (ROI) could be determined for tumor growth and the metabolization of <sup>18</sup>F-FDG.



**Figure 3:** Tumor volume growth curve

**Figure 3A:** Tumor uptake of 18F-FDG.

**Figure 3B:** Were determined by microPET images. Recorded on all animals after implanted LL2 cells (D21) to the study period (D28). (n = 3, mean ± SD).

## Cytokine Assays

The levels of serum cytokines were analyzed using the Bio-Plex system. The serum cytokine levels in the X-911-fed mice and the control mice are shown in Table 2. Comparing these two groups, the levels of cytokines released predominantly from TH1 cells, such

as IL2 and IFN- $\gamma$ , did not differ significantly, and the results were similar for IL4 and IL5, although IL1 $\beta$  and IL10 differed between the two groups. However, TNF- $\alpha$  and GM-CSF were significantly higher in the X-911-fed mice than in the control mice ( $P = 0.03$  and  $P = 0.01$ , respectively).

**Table 2:** Comparison results of serum cytokines with X-911 (0.25g/mL) feeding mice and control group (n = 3).

(μg/mL)	X-911		Control		p-value
	Average	Range	Average	Range	
IL-1 $\beta$	675.78	364.66-1373.30	251.37	64.96-407.88	0.14
IL-2	8.49	5.75-10.78	8.06	6.05-10.78	0.75
IFN- $\gamma$	4.39	3.49-5.14	5.34	3.68-6.96	0.34
GM-CSF	3.86	3.60-4.18	2.93	2.45-3.39	0.01
TNF- $\alpha$	6886.87	2980.84-10903.97	1016.4	770.38-1799.01	0.03
IL-4	1.25	0.78-1.67	1.44	0.89-2.35	0.6
IL-5	17.88	29.51-10.76	16.07	7.96-27.52	0.77
IL-10	3.83	1.49-5.66	2.33	1.59-3.10	0.25

## Discussion

PET with  $^{18}\text{F}$ -FDG plays an important role in imaging malignant tumors because  $^{18}\text{F}$ -FDG imaging visualizes the glucose metabolic activity of the tissues and can be used to monitor tumor responses to therapy [11,12]. In this study, we used  $^{18}\text{F}$ -FDG to measure the volumes of the tumors in vivo and determine whether they were associated with a specific tumor microenvironment, such as hypoxia or increased cellular proliferation. By measuring the tumor sizes daily along three orthogonal diameters and comparing these with  $^{18}\text{F}$ -FDG data, the spatial information for tumor growth under different conditions was similar when acquired with microPET imaging and physical measurements.

$^{18}\text{F}$ -FDG can detect an enhanced glycolytic reaction, which is often associated with the growth rate and malignancy potential of a tumor [13]. With microPET imaging, we identified a difference between day 21 and day 28 when the X-911 treatment was extended for a long time. We obtained excellent results with microPET, which demonstrated that X-911 caused a significant reduction in tumor growth between conditions 1 to 4 and 5 (Figure 3) but did not affect the metabolic activity of the tumors because there was no significant difference in  $^{18}\text{F}$ -FDG uptake. Therefore, X-911, a traditional Chinese medicine, can inhibit tumor growth but does not change the metabolism of the surviving cells.

A previous study showed that traditional Chinese medicines could be used in sport to relieve exhaustion, increase athletic prowess, and increase the blood vessels required to carry the

nutrients essential for the rapid growth of solid tumors [14]. During tumor growth, the immune system is balanced between the Th1 (autoimmune) and Th2 (pregnancy or suppressive) responses, which are important in influencing the outcome. Th1 and Th2 cells are essential regulators of the classes of immune responses that function in human immunity. TNF- $\alpha$  and GM-CSF are the signature cytokines of  $T_H1$  cells, which induce an immune response directed against immunogenic tumor cells. Our results indicate that the protective activity of X-911 might be based on increasing the levels of serum TNF- $\alpha$  and GM-CSF.

## Conclusions

This study has shown that X-911, a traditional Chinese medicine, can alter the balance between Th1 and Th2 cells. X-911 increased the levels of the serum cytokines released from  $T_H1$  cells, thus inhibiting tumor cell growth. We also successfully monitored tumor formation and tumor metabolism using  $^{18}\text{F}$ -FDG/microPET. In assessing tumor development, the physical measurements were similar to those made with microPET imaging. However, only  $^{18}\text{F}$ -FDG/microPET can identify the tumor metabolic status in vivo. The glucose uptake of the surviving cells did not differ from that of normal cells. To further investigate the antitumor activity of X-911, we plan to use different kinds of tumors to compare their mechanisms.

## Disclosure Policy

The authors declare that they have no conflict of interests regarding the publication of this paper.

## References

1. SM Lee, ML Li, Tse YC, Leung SC, Lee MM, et al. (2002) Paeoniae Radix, a Chinese herbal extract, inhibit hepatoma cells growth by inducing apoptosis in a p53 independent pathway. *Life Sci* 71: 2267–2277.
2. Wu Y, Zhang Y, Wu JA, Lowell T, Gu M, et al. (1998) Effects of Erkang, a modified formulation of Chinese folk medicine Shi-Quan-Da-Bu-Tang, on mice. *J Ethnopharmacol* 61: 153–159.
3. Bouic PJ, Etsebeth S, Liebenberg RW, Albrecht CF, Pegel K, et al. (1996) Beta-Sitosterol and beta-sitosterol glucoside stimulate human peripheral blood lymphocyte proliferation: Implications for their use as an immunomodulatory vitamin combination. *Int J Immunopharmacol* 18: 693–700.
4. Huang ST, Yang RC, Lee PN, Yang SH, Liao SK, et al. (2006) Anti-tumor and anti-angiogenic effects of *Phyllanthus urinaria* in mice bearing Lewis lung carcinoma. *Int Immunopharmacol* 6(6): 870–879.
5. Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, et al. (2005) The role of TGF-beta 1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model. *Journal of Ethnopharmacology* 97(1): 7–13.
6. Ohtake N, Suzuki R, Daikuhara H, Nakai Y, Yamamoto M, et al. (2000) Modulation of lung local immune responses by oral administration of a herbal medicine Sho-saiko-to. *Int J Immunopharmacol* 22(6): 419–430.
7. Bouic PJ (2002) Sterols and sterolins: new drugs for the immune system? *Drug Discov Today* 7(14): 775–778.
8. Kung HF, Kung MP, Zhuang ZP, Hou C, Lee CW, et al. (2003) Iodinated tracers for imaging amyloid plaques in the brain. *Mol Imaging Biol* 5(6): 418–426.
9. Wong CY, Schmidt J, Bong JS (2007) Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging. *Radiat Oncol* 2: 18.
10. Song SL, Liu JJ (2008) Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model. *J Nucl Med* 49: 303–309.
11. Ho JC, Konerding MA, Gaumann A, Groth M, Liu WK, et al. (2004) Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice. *Life Sci* 75(11): 1343–1356.
12. Ardavin C, Martinez del Hoyo G, Martin P, F Anjuère, C F Arias, et al. (2001) Origin and differentiation of dendritic cells. *Trends in Immunology* 22(12): 691–700.
13. Eksioglu EA, Mahmood SS, Chang M, Reddy V (2007) GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. *Exp Hematol* 35(8): 1163–1171.
14. Everly JJ, Lonial S (2005) Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumor activity. *Expert Opinion on Biological Therapy* 5(3): 293–311.